{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001194","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.966325+00:00","generated_at":"2026-06-07T02:06:43.609107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M","bullets":["Q4 2023 preliminary revenue $72-74M; full year $256-258M.","FY2024 revenue guidance raised to >$320M from $290M; FY2025 to >$370M from $335M.","FY2024 net income expected >$60M (from $55M) and adjusted EBITDA ~$85M.","New growth: manufacturing yield enhancement and S. pneumonia hyperimmune globulin (potential peak revenue $300-500M).","ASCENIV label expansion via pediatric study progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001194","json":"https://secwatch.observer/filing/0001140361-24-001194.json","markdown":"https://secwatch.observer/filing/0001140361-24-001194.md","text":"https://secwatch.observer/filing/0001140361-24-001194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/0001140361-24-001194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/ef20018240_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:06:43.609107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"11feb44288aca7e376a86d967320bcc9e0ea6da7","claim":"ADMA BIOLOGICS, INC. reported fourth quarter and full year 2023 results: revenue $72-74 Million. Guidance raised.","evidence_excerpt":"ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124001194/0001140361-24-001194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Revenue","value":"$72-74 Million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}